Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study pinpoints oliceridine dose to keep blood pressure steady during intubation

NCT ID NCT07154979

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested different doses of oliceridine, a painkiller, to find the amount that best prevents sudden rises in blood pressure and heart rate when a breathing tube is placed during anesthesia. Researchers enrolled 58 adults having elective surgery and adjusted doses based on age. The goal was to identify the effective dose for safer anesthesia induction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oliceridine (TRV130)
What this could lead to
If successful, this could help doctors choose the safest dose of oliceridine to prevent dangerous blood pressure spikes during anesthesia, especially for older patients.
What could go wrong
This is a small, completed dose-finding study, not a large trial testing long-term outcomes. The results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

58 people

The number who actually took part.

Started

Sep 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Elective surgery requiring general anesthesia with tracheal intubation * Age ≥ 18 years * American Society of Anesthesiologists (ASA) physical status I-III * BMI\<25 Exclusion Criteria: * At rest in the operating room, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 110 mmHg or heart rate ≥ 110 bpm * Preoperative long-term use of analgesic or sedative medications * Pregnancy, breastfeeding, known or planned pregnancy * Known allergy or hypersensitivity to oliceridine or any study medication components * History of psychiatric illness or inability to communicate effectively

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oliceridine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianmen First People's Hospital

    Tianmen, Hubei, 431700, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.